David Dingli
- Hematology top 0.02%
- Multiple Myeloma Research and Treatments 218
- Chronic Myeloid Leukemia Treatments 54
- Genetics top 0.1%
- Myeloproliferative Neoplasms: Diagnosis and Treatment 51
- Chronic Lymphocytic Leukemia Research 41
- Oncology top 0.2%
- Cancer Treatment and Pharmacology 52
- Peptidase Inhibition and Analysis 50
- Nephrology top 0.5%
- Molecular Biology top 0.5%
- Amyloidosis: Diagnosis, Treatment, Outcomes 116
- Protein Degradation and Inhibitors 65
- Co-authors
- Morie A. GertzAngela DispenzieriMartha Q. LacyShaji KumarFrancis K. BuadiStephen J. RussellSuzanne R. HaymanS. Vincent Rajkumar
- Cited by
- HematologyGeneticsOncology
- Journals
- Blood (109 papers)Journal of Clinical Oncology (43 papers)American Journal of Hematology (33 papers)
- Partner nations
- United StatesPortugalGermany
In The Last Decade
David Dingli
439 papers receiving 14.5k citations
Hit Papers
Peers
Comparison fields: 5 of 155
- Hematology 8.0k
- Genetics 2.7k
- Oncology 5.3k
- Nephrology 964
- Molecular Biology 8.9k
Countries citing papers authored by David Dingli
This map shows the geographic impact of David Dingli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Dingli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Dingli more than expected).
Fields of papers citing papers by David Dingli
This network shows the impact of papers produced by David Dingli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Dingli. The network helps show where David Dingli may publish in the future.
Co-authorship network
The 25 scholars most cited alongside David Dingli, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 1 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 13 | |
| 7 | 2022 | 2 | |
| 8 | 2021 | 4 | |
| 9 | 2021 | 6 | |
| 10 | 2021 | 2 | |
| 11 | 2020 | 12 | |
| 12 | 2019 | 12 | |
| 13 | 2019 | 13 | |
| 14 | 2019 | 31 | |
| 15 | 2019 | 11 | |
| 16 | 2018 | 12 | |
| 17 | 2015 | 22 | |
| 18 | 2013 | 120 | |
| 19 | Therapeutic Strategies For Initial Treatment Of AL Amyloidosis: Implications Of Therapy and Response On Outcome | 2013 | 2 |
| 20 | 2009 | 226 |
About David Dingli
David Dingli is a scholar working on Hematology, Genetics and Oncology, having authored 465 papers that have together received 14.8k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (218 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (116 papers), Protein Degradation and Inhibitors (65 papers), Chronic Myeloid Leukemia Treatments (54 papers), Cancer Treatment and Pharmacology (52 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (51 papers), Peptidase Inhibition and Analysis (50 papers) and Chronic Lymphocytic Leukemia Research (41 papers). The work is most often cited by research in Hematology (8.0k citations), Genetics (2.7k citations) and Oncology (5.3k citations). David Dingli has collaborated with scholars based in United States, Portugal and Germany. Frequent co-authors include Morie A. Gertz, Angela Dispenzieri, Martha Q. Lacy, Shaji Kumar, Francis K. Buadi, Stephen J. Russell, Suzanne R. Hayman, S. Vincent Rajkumar, Robert A. Kyle and John A. Lust. Their work appears in journals such as Blood, Journal of Clinical Oncology, American Journal of Hematology, Bone Marrow Transplantation and Blood Cancer Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.